Celiac disease

Pathogenesis and serologic tests

Research output: Contribution to journalArticle

Abstract

The serological tests represent a significant advance in screening at-risk patients for celiac disease and probably should supplant other nonspecific methods for screening, such as 72-hr fecal fat, the d-xylose test, serum carotene, or small-bowel x-ray. The latter tests lack sensitivity, specificity, or simplicity. The published results suggest that the EMA IgA IFA is currently the screening tool of choice. The demonstration of the characteristic histological abnormalities of the intestinal abnormality and clinical improvement on a gluten-free diet is the gold standard for the diagnosis of celiac disease. Whether serological testing can substitute for intestinal biopsy in the diagnosis of celiac disease will depend on the experience obtained from more widespread application of these tests. The greater availability and more frequent use of these tests should increase the detection of a readily treatable condition, the diagnosis of which is often greatly delayed.

Original languageEnglish (US)
Pages (from-to)105-112
Number of pages8
JournalClinical Immunology Newsletter
Volume13
Issue number9-10
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Celiac Disease
Serologic Tests
Gluten-Free Diet
Xylose
Carotenoids
Immunoglobulin A
Fats
X-Rays
Biopsy
Sensitivity and Specificity
Serum

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Celiac disease : Pathogenesis and serologic tests. / Murray, Joseph A.

In: Clinical Immunology Newsletter, Vol. 13, No. 9-10, 1993, p. 105-112.

Research output: Contribution to journalArticle

@article{2069c25235854e4d8d492f158038d3e1,
title = "Celiac disease: Pathogenesis and serologic tests",
abstract = "The serological tests represent a significant advance in screening at-risk patients for celiac disease and probably should supplant other nonspecific methods for screening, such as 72-hr fecal fat, the d-xylose test, serum carotene, or small-bowel x-ray. The latter tests lack sensitivity, specificity, or simplicity. The published results suggest that the EMA IgA IFA is currently the screening tool of choice. The demonstration of the characteristic histological abnormalities of the intestinal abnormality and clinical improvement on a gluten-free diet is the gold standard for the diagnosis of celiac disease. Whether serological testing can substitute for intestinal biopsy in the diagnosis of celiac disease will depend on the experience obtained from more widespread application of these tests. The greater availability and more frequent use of these tests should increase the detection of a readily treatable condition, the diagnosis of which is often greatly delayed.",
author = "Murray, {Joseph A}",
year = "1993",
doi = "10.1016/0197-1859(93)90025-F",
language = "English (US)",
volume = "13",
pages = "105--112",
journal = "Clinical Immunology Newsletter",
issn = "0197-1859",
publisher = "Elsevier BV",
number = "9-10",

}

TY - JOUR

T1 - Celiac disease

T2 - Pathogenesis and serologic tests

AU - Murray, Joseph A

PY - 1993

Y1 - 1993

N2 - The serological tests represent a significant advance in screening at-risk patients for celiac disease and probably should supplant other nonspecific methods for screening, such as 72-hr fecal fat, the d-xylose test, serum carotene, or small-bowel x-ray. The latter tests lack sensitivity, specificity, or simplicity. The published results suggest that the EMA IgA IFA is currently the screening tool of choice. The demonstration of the characteristic histological abnormalities of the intestinal abnormality and clinical improvement on a gluten-free diet is the gold standard for the diagnosis of celiac disease. Whether serological testing can substitute for intestinal biopsy in the diagnosis of celiac disease will depend on the experience obtained from more widespread application of these tests. The greater availability and more frequent use of these tests should increase the detection of a readily treatable condition, the diagnosis of which is often greatly delayed.

AB - The serological tests represent a significant advance in screening at-risk patients for celiac disease and probably should supplant other nonspecific methods for screening, such as 72-hr fecal fat, the d-xylose test, serum carotene, or small-bowel x-ray. The latter tests lack sensitivity, specificity, or simplicity. The published results suggest that the EMA IgA IFA is currently the screening tool of choice. The demonstration of the characteristic histological abnormalities of the intestinal abnormality and clinical improvement on a gluten-free diet is the gold standard for the diagnosis of celiac disease. Whether serological testing can substitute for intestinal biopsy in the diagnosis of celiac disease will depend on the experience obtained from more widespread application of these tests. The greater availability and more frequent use of these tests should increase the detection of a readily treatable condition, the diagnosis of which is often greatly delayed.

UR - http://www.scopus.com/inward/record.url?scp=43949165717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43949165717&partnerID=8YFLogxK

U2 - 10.1016/0197-1859(93)90025-F

DO - 10.1016/0197-1859(93)90025-F

M3 - Article

VL - 13

SP - 105

EP - 112

JO - Clinical Immunology Newsletter

JF - Clinical Immunology Newsletter

SN - 0197-1859

IS - 9-10

ER -